Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 4.8%

Share on StockTwits

Shares of Hemogenyx Pharmaceuticals PLC (LON:HEMO) fell 4.8% on Wednesday . The company traded as low as GBX 1.96 ($0.03) and last traded at GBX 2 ($0.03), 494,766 shares traded hands during trading. A decline of 94% from the average session volume of 8,010,000 shares. The stock had previously closed at GBX 2.10 ($0.03).

The firm has a market capitalization of $7.23 million and a price-to-earnings ratio of -5.00. The business has a 50-day moving average of GBX 2.09 and a two-hundred day moving average of GBX 2.53. The company has a quick ratio of 12.36, a current ratio of 12.36 and a debt-to-equity ratio of 415.66.

Hemogenyx Pharmaceuticals Company Profile (LON:HEMO)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants.

Recommended Story: How Do Tariffs Affect Trade Balances?

Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Convergence Investment Partners LLC Sells 1,507 Shares of Verizon Communications Inc.
Convergence Investment Partners LLC Sells 1,507 Shares of Verizon Communications Inc.
Convergence Investment Partners LLC Sells 26,972 Shares of Intel Co.
Convergence Investment Partners LLC Sells 26,972 Shares of Intel Co.
Target Hospitality  Upgraded by Zacks Investment Research to Hold
Target Hospitality Upgraded by Zacks Investment Research to Hold
Travelers Companies  Now Covered by Citigroup
Travelers Companies Now Covered by Citigroup
Zacks Investment Research Upgrades Ultrapar Participacoes  to “Buy”
Zacks Investment Research Upgrades Ultrapar Participacoes to “Buy”
Visa  Now Covered by Macquarie
Visa Now Covered by Macquarie


© 2006-2020 Ticker Report